- Home
- Publications
- Publication Search
- Publication Details
Title
Theranostics for Triple-Negative Breast Cancer
Authors
Keywords
-
Journal
Diagnostics
Volume 13, Issue 2, Pages 272
Publisher
MDPI AG
Online
2023-01-11
DOI
10.3390/diagnostics13020272
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer statistics, 2022
- (2022) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
- (2021) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chitosan oligosaccharide decorated liposomes combined with TH302 for photodynamic therapy in triple negative breast cancer
- (2021) Yinan Ding et al. JOURNAL OF NANOBIOTECHNOLOGY
- Carbon nanotubes (CNT)-loaded ginsenosides Rb3 suppresses the PD-1/PD-L1 pathway in triple-negative breast cancer
- (2021) Xiao Luo et al. Aging-US
- Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
- (2021) D. Miles et al. ANNALS OF ONCOLOGY
- Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer
- (2021) Andrew N.J. Tutt et al. NEW ENGLAND JOURNAL OF MEDICINE
- Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer
- (2021) Peiqi Zhao et al. JOURNAL OF NANOBIOTECHNOLOGY
- Recent advances of nanotechnology in the diagnosis and therapy of triple-negative breast cancer (TNBC)
- (2021) Abhishek Kanugo et al. CURRENT PHARMACEUTICAL BIOTECHNOLOGY
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Talazoparib nanoparticles for overcoming multidrug resistance in triple‐negative breast cancer
- (2020) Gamze Guney Eskiler et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer
- (2020) K.G.K. Deepak et al. PHARMACOLOGICAL RESEARCH
- Curcumin-Loaded Solid Lipid Nanoparticles Bypass P-Glycoprotein Mediated Doxorubicin Resistance in Triple Negative Breast Cancer Cells
- (2020) Gamal-Eldein Fathy Abd-Ellatef et al. Pharmaceutics
- Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
- (2020) Mauricio A. Medina et al. International Journal of Environmental Research and Public Health
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2020) Véronique Diéras et al. LANCET ONCOLOGY
- Triple-negative breast cancer: new treatment strategies in the era of precision medicine
- (2020) Song-Yang Wu et al. Science China-Life Sciences
- Emerging Nanopharmaceuticals and Nanonutraceuticals in Cancer Management
- (2020) Lavinia Salama et al. Biomedicines
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- DR5 antibody conjugated lipid-based nanocarriers of gamma-secretase inhibitor for the treatment of triple negative breast cancer
- (2020) Sai Kiran S.S. Pindiprolu et al. CHEMISTRY AND PHYSICS OF LIPIDS
- Tumor microenvironment as a therapeutic target in cancer
- (2020) Yi Xiao et al. PHARMACOLOGY & THERAPEUTICS
- Dendrimer mediated targeting of siRNA against polo‐like kinase for the treatment of triple negative breast cancer
- (2019) Anjali Jain et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Talazoparib Loaded Solid Lipid Nanoparticles: Preparation, Characterization and Evaluation the Therapeutic Efficacy In Vitro
- (2019) Gamze Guney Eskilera et al. Current Drug Delivery
- Remodeling the Tumor Microenvironment Sensitizes Breast Tumors to Anti- Programmed Death-Ligand 1 Immunotherapy
- (2019) Renee Clift et al. CANCER RESEARCH
- Recent advances in nanotheranostics for triple negative breast cancer treatment
- (2019) Vikram Thakur et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Eradication of cancer stem cells in triple negative breast cancer using doxorubicin/pluronic polymeric micelles
- (2019) Yi Zhao et al. Nanomedicine-Nanotechnology Biology and Medicine
- Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification
- (2018) Isabel Echavarria et al. CLINICAL CANCER RESEARCH
- Precision Medicine: From Science To Value
- (2018) Geoffrey S. Ginsburg et al. HEALTH AFFAIRS
- Biomimetic peptide display from a polymeric nanoparticle surface for targeting and antitumor activity to human triple-negative breast cancer cells
- (2018) Eric M. Bressler et al. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A
- Recent Advances in the Treatment of Breast Cancer
- (2018) Christy W. S. Tong et al. Frontiers in Oncology
- Proportion of U.S. Trends in Breast Cancer Incidence Attributable to Long-term Changes in Risk Factor Distributions
- (2018) Ruth M. Pfeiffer et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer
- (2018) Leisha A. Emens et al. JAMA Oncology
- Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study
- (2018) S Adams et al. ANNALS OF ONCOLOGY
- Investigation of the antitumor activity and toxicity of long-circulating and fusogenic liposomes co-encapsulating paclitaxel and doxorubicin in a murine breast cancer animal model
- (2018) Marina Santiago Franco et al. BIOMEDICINE & PHARMACOTHERAPY
- A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
- (2018) Miguel F. Sanmamed et al. CELL
- Classification of triple-negative breast cancers based on Immunogenomic profiling
- (2018) Yin He et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
- (2018) Todd A. Hopkins et al. MOLECULAR CANCER RESEARCH
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up
- (2018) Sylvia Adams et al. JAMA Oncology
- Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
- (2017) Aditya Bardia et al. JOURNAL OF CLINICAL ONCOLOGY
- Carbon nanotubes: A review of novel strategies for cancer diagnosis and treatment
- (2017) Mojgan Sheikhpour et al. Materials Science & Engineering C-Materials for Biological Applications
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Conditional internalization of PEGylated nanomedicines by PEG engagers for triple negative breast cancer therapy
- (2017) Yu-Cheng Su et al. Nature Communications
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors
- (2016) Xiumei Huang et al. CANCER CELL
- Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents – A Potential Therapy for Cancer
- (2016) Nidal E. Muvarak et al. CANCER CELL
- Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
- (2016) Haidong Tang et al. CANCER CELL
- Nanoparticles for imaging and treatment of metastatic breast cancer
- (2016) Qingxin Mu et al. Expert Opinion on Drug Delivery
- Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome
- (2016) Rhiannon K Beckers et al. HISTOPATHOLOGY
- Multi-walled nanotubes for cellular reprogramming of cancer
- (2016) Elizabeth M. Wailes et al. Nanomedicine-Nanotechnology Biology and Medicine
- BRCAness as a Biomarker for Predicting Prognosis and Response to Anthracycline-Based Adjuvant Chemotherapy for Patients with Triple-Negative Breast Cancer
- (2016) Hitomi Mori et al. PLoS One
- Nanocarriers for cancer-targeted drug delivery
- (2015) Preeti Kumari et al. JOURNAL OF DRUG TARGETING
- Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation
- (2015) Terrick Andey et al. MOLECULAR PHARMACEUTICS
- Quantum dot-based in situ simultaneous molecular imaging and quantitative analysis of EGFR and collagen IV and identification of their prognostic value in triple-negative breast cancer
- (2015) Hong-Mei Zheng et al. TUMOR BIOLOGY
- Polymeric Micelles for Multi-Drug Delivery in Cancer
- (2014) Hyunah Cho et al. AAPS PHARMSCITECH
- Polymeric Micelles: Nanocarriers for Cancer-Targeted Drug Delivery
- (2014) Yifei Zhang et al. AAPS PHARMSCITECH
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer
- (2014) Wenbing Dai et al. BIOMATERIALS
- Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors
- (2013) A. F. Schott et al. CLINICAL CANCER RESEARCH
- Liposome: classification, preparation, and applications
- (2013) Abolfazl Akbarzadeh et al. Nanoscale Research Letters
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Heterogeneity of Triple-Negative Breast Cancer: Histologic Subtyping to Inform the Outcome
- (2012) Emilia Montagna et al. Clinical Breast Cancer
- Nanobiopolymer for Direct Targeting and Inhibition of EGFR Expression in Triple Negative Breast Cancer
- (2012) Satoshi Inoue et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
- (2011) A. M. Gonzalez-Angulo et al. CLINICAL CANCER RESEARCH
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
- (2011) Thomas Helleday Molecular Oncology
- Generation 4 polyamidoamine dendrimers is a novel candidate of nano-carrier for gene delivery agents in breast cancer treatment
- (2010) Pei Wang et al. CANCER LETTERS
- Synergistic Chemosensitivity of Triple-Negative Breast Cancer Cell Lines to Poly(ADP-Ribose) Polymerase Inhibition, Gemcitabine, and Cisplatin
- (2010) K. Hastak et al. CANCER RESEARCH
- A phase 2 study of SP1049C, doxorubicin in P-glycoprotein-targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction
- (2010) Juan W. Valle et al. INVESTIGATIONAL NEW DRUGS
- High performance in vivo near-IR (>1 μm) imaging and photothermal cancer therapy with carbon nanotubes
- (2010) Joshua T. Robinson et al. Nano Research
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- Solid lipid nanoparticles: A modern formulation approach in drug delivery system
- (2009) S Mukherjee et al. INDIAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Differential metabolic responses to pluronic in MDR and non-MDR cells: A novel pathway for chemosensitization of drug resistant cancers
- (2009) Daria Yu. Alakhova et al. JOURNAL OF CONTROLLED RELEASE
- Activated and non-activated PAMAM dendrimers for gene delivery in vitro and in vivo
- (2009) Gemma Navarro et al. Nanomedicine-Nanotechnology Biology and Medicine
- Carbon nanotubes as photoacoustic molecular imaging agents in living mice
- (2008) Adam De La Zerda et al. Nature Nanotechnology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More